The sensitivity of tumors with HRR mutations (HRRm), including BRCA1, BRCA2, PALB2, and RAD51C, to PARPi has been reported in preclinical research (14), as well as clinically (15, 16), across tumor types (Supplementary Table S1). This evidence concerns the gene RAD51C and neoplasm.